Psoriatic Arthritis Patients Achieving Robust Treatment Targets Experience Better Outcomes
The PsABio study sought to evaluate the real-world effectiveness and safety of ustekinumab (UST) and tumor necrosis factor inhibitors (TNFi) over three years in treating psoriatic arthritis (PsA).